SCHEMBL2420679

SCHEMBL2420679

CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.56
DUSP3 P51452 1/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
LMNA P02545 1/20 0.56
LPAR1 Q92633 6/20 0.55
LPAR6 P43657 1/20 0.53
LPAR4 Q99677 1/20 0.53
LPAR5 Q9H1C0 1/20 0.53
LPAR2 Q9HBW0 1/20 0.53
LPAR3 Q9UBY5 1/20 0.53
ENPP2 Q13822 1/20 0.53
MAPT P10636 1/20 0.51
ADRB2 P07550 1/20 0.49
ADRB1 P08588 1/20 0.49
ADRB3 P13945 1/20 0.49
DGKA P23743 1/20 0.49
P2RY10 O00398 2/20 0.48
GPR174 Q9BXC1 2/20 0.48
GPR34 Q9UPC5 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31294962 1.00 KDM4E (0.56) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL31294933 1.00 KDM4E (0.56) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL31294961 1.00 KDM4E (0.56) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL19017557 1.00 KDM4E (0.56) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL28495035 1.00 KDM4E (0.56) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL31294925 0.91 LMNA (0.51) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL31294935 0.91 LMNA (0.51) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL31294921 0.91 LMNA (0.51) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL31294936 0.91 LMNA (0.51) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL25477324 0.88 MAPT (0.49) KDM4EDUSP3MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846880-B2 Synthetic analogues of phosphatidyl-myo-inositol mannosides with an inhibitory activity of the inflammatory response Centre National de la Recherche Scientifique—CNRS— (FR) 2014-09-30 US disclosed
EP-2280986-B1 SYNTHETIC ANALOGUES OF PHOSPHATIDYL-MYO-INOSITOL MANNOSIDES WITH AN INHIBITORY ACTIVITY ON THE INFLAMMATORY RESPONSE CENTRE NAT RECH SCIENT (FR) 2013-07-10 EP disclosed
US-20110224162-A1 SYNTHETIC ANALOGUES OF PHOSPHATIDYL-MYO-INOSITOL MANNOSIDES WITH AN INHIBITORY ACTIVITY OF THE INFLAMMATORY RESPONSE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS- (FR) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224162-A1 SYNTHETIC ANALOGUES OF PHOSPHATIDYL-MYO-INOSITOL MANNOSIDES WITH AN INHIBITORY ACTIVITY OF THE INFLAMMATORY RESPONSE MIF, MPI, PHOSPHO1 KDM4E 3938/4885DUSP3 408/4885MEN1 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.